Abstract
A total of 11 children (five males and six females) with hypergranular type of acute promyelocytic leukemia (APML) were treated with intravenous arsenic trioxide (As2O3) between December 1998 and October 2003. Eight cycles of As2O3 (0.15 mg/kg/day) were administered (induction, consolidation and six cycles of maintenance) over a period of 12 months. The median WBC count at diagnosis was 3400/mm3 (range: 800–9800). In all, 10 patients (91%) achieved hematological remission at a mean duration of 48 days (range: 41–60) with all 10 patients achieving molecular remission at a median duration of 81 days (range: 64–109). Toxicity was minimal with leukocytosis in six patients, ichthyosis and hyperpigmentation of skin in five and mild peripheral neuropathy in one patient. One patient who relapsed 6 months after completing therapy achieved a second hematological and molecular remission with As2O3. With a median follow-up of 30 months (range: 4–62), the overall (OS) survival is 91% with a relapse-free survival (RFS) of 81%. As2O3 achieves hematological and molecular remission in majority of newly diagnosed children with APML with minimal toxicity, but long-term follow-up is required to evaluate late effects of As2O3 and study the minimum dose and duration required for a sustained remission.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gregory Jr J, Feusner J . Acute promyelocytic leukemia in children. Best Practice Res Clin Haematol 2003; 16: 483–494.
Mann G, Reinhardt D, Ritter J, Hermann J, Schmitt K, Gadner H et al. Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Haematol 2001; 80: 417–422.
Biondi A, Rovelli A, Cantu-Rajnodi A, Fenu S, Basso G, Luciano A et al. Acute promyelocytic leukemia in children: experience of the Italian Paediatric Hematology and Oncology Group (AIEOP). Leukemia 1994; 8: 1264–1268.
Bapna A, Nair R, Tapan KS, Nair CN, Kadam P, Gladstone B et al. All-trans-retinoic acid (ATRA): pediatric acute promyelocytic leukemia. Pediatr Hematol Oncol 1998; 15: 243–248.
Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999; 94: 3015–3021.
Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014–1021.
Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS et al. Studies on treatment of acute promyelocytic leukemia with arsenic tri-oxide: remission induction, follow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315–3324.
Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852–3860.
Mathews V, Balasubramaniam P, Shaji RV, George B, Chandy M, Srivastava A . Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol 2002; 70: 292–299.
Zhang P, Wang S, Hu L, Qiu F, Yang H, Xiao Y et al. Seven years summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide – an analysis of 242 cases. Zhonghua Xue Ye Xue Za Zhi 2000; 21: 67–70.
Hu X, Ma L, Hu N . Ailing No 1. in treating 62 cases of acute promyelocytic leukemia. Zhongguo Zhong Xi Yi Jie He Za Zhi 1999; 19: 473–476.
van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease: report of the BIOMED – 1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901–1928.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
George, B., Mathews, V., Poonkuzhali, B. et al. Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. Leukemia 18, 1587–1590 (2004). https://doi.org/10.1038/sj.leu.2403480
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403480
Keywords
This article is cited by
-
Arsenic trioxide: applications, mechanisms of action, toxicity and rescue strategies to date
Archives of Pharmacal Research (2024)
-
Acute promyelocytic leukemia current treatment algorithms
Blood Cancer Journal (2021)
-
Management of patients with acute promyelocytic leukemia
Leukemia (2018)
-
Promyelocytic leukemia protein in mesenchymal stem cells is essential for leukemia progression
Annals of Hematology (2018)
-
How to manage acute promyelocytic leukemia
Leukemia (2012)